Cellosaurus 5637 (CVCL_0126)

Cell line name 5637
Accession CVCL_0126
Resource Identification Initiative To cite this cell line use: 5637 (RRID:CVCL_0126)
Comments Part of: BLA-40 bladder carcinoma cell line panel.
Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: ERK genetic alteration cell panel (ATCC TCP-1033).
Part of: UBC-40 urothelial bladder cancer cell line index.
Doubling time: 23 hours (PubMed=26055179); ~24 hours (DSMZ).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: GPI-anchored proteins analysis by proteomics.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Misspelling: HTB9; Based on the ATCC catalog number.
Sequence variations Heterozygous for MAPK1 p.Arg79Lys (ATCC).
TERT c.228C>T (-124C>T); in promoter (PubMed=24035680).
TP53 p.Arg280Thr (c.839G>C) (PubMed=9850064).
Disease Bladder carcinoma (NCIt: C4912)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_6344 (1A6)CVCL_JE91 (H/Rb-CL2)CVCL_JE92 (H/Rb-M)
Sex of cell Male
Age at sampling 68Y
Category Cancer cell line
STR profile Source(s): ATCC; CLS; Cosmic-CLP; DSMZ; KCLB; PubMed=11416159; PubMed=17254797; RCB; TKG

Markers:
AmelogeninX,Y
CSF1PO11
D13S31711
D16S5399
D18S5116,18
D21S1136
D3S135815,17
D5S81811,12
D7S82010,11
D8S117910,16
FGA22
Penta D11
Penta E10,12
TH017,9
TPOX8,9
vWA16,18 (ATCC; Cosmic-CLP; TKG)
18 (CLS; DSMZ; KCLB; PubMed=11416159; PubMed=17254797; RCB)
Web pages http://www.cells-talk.com/index.php/page/copelibrary?key=5637
http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/5/cell-lines-detail-354.html
Publications

PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=6244232
Williams R.D.
Human urologic cancer cell lines.
Invest. Urol. 17:359-363(1980)

PubMed=7459858
Rousset M., Zweibaum A., Fogh J.
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Cancer Res. 41:1165-1170(1981)

PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=8873383; DOI=10.1007/BF00295899
Stadler W.M., Olopade O.I.
The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes.
Urol. Res. 24:239-244(1996)

PubMed=9850064
Markl I.D.C., Jones P.A.
Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer.
Cancer Res. 58:5348-5353(1998)

PubMed=11921286; DOI=10.1002/gcc.10050
Williams S.V., Sibley K.D., Davies A.M., Nishiyama H., Hornigold N., Coulter J., Kennedy W.J., Skilleter A., Habuchi T., Knowles M.A.
Molecular genetic analysis of chromosome 9 candidate tumor-suppressor loci in bladder cancer cell lines.
Genes Chromosomes Cancer 34:86-96(2002)

PubMed=12127398; DOI=10.1016/S0165-4608(01)00648-3
Strefford J.C., Lillington D.M., Steggall M., Lane T.M., Nouri A.M.E., Young B.D., Oliver R.T.D.
Novel chromosome findings in bladder cancer cell lines detected with multiplex fluorescence in situ hybridization.
Cancer Genet. Cytogenet. 135:139-146(2002)

PubMed=15846775; DOI=10.1002/gcc.20166
Williams S.V., Adams J., Coulter J., Summersgill B.M., Shipley J., Knowles M.A.
Assessment by M-FISH of karyotypic complexity and cytogenetic evolution in bladder cancer in vitro.
Genes Chromosomes Cancer 43:315-328(2005)

PubMed=16885334; DOI=10.1158/0008-5472.CAN-06-1182
Lopez-Knowles E., Hernandez S., Malats N., Kogevinas M., Lloreta J., Carrato A., Tardon A., Serra C., Real F.X.
PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
Cancer Res. 66:7401-7404(2006)

PubMed=17254797; DOI=10.1016/j.biologicals.2006.10.001
Azari S., Ahmadi N., Tehrani M.J., Shokri F.
Profiling and authentication of human cell lines using short tandem repeat (STR) loci: report from the National Cell Bank of Iran.
Biologicals 35:195-202(2007)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23401075; DOI=10.1002/path.4176
Guo Y., Chekaluk Y., Zhang J., Du J., Gray N.S., Wu C.-L., Kwiatkowski D.J.
TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.
J. Pathol. 230:17-27(2013)

PubMed=24367658; DOI=10.1371/journal.pone.0084411
Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H., Knowles M.A.
Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
PLoS ONE 8:E84411-E84411(2013)

PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057
Hurst C.D., Platt F.M., Knowles M.A.
Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.
Eur. Urol. 65:367-369(2014)

PubMed=24459064; DOI=10.1007/s13277-013-1604-3
Pinto-Leite R., Carreira I., Melo J., Ferreira S.I., Ribeiro I., Ferreira J., Filipe M., Bernardo C., Arantes-Rodrigues R., Oliveira P., Santos L.
Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer.
Tumor Biol. 35:4599-4617(2014)

PubMed=25997541; DOI=10.1186/s12864-015-1450-3
Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B., Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G., Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D., Chanock S., Valencia A., Real F.X.
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
BMC Genomics 16:403-403(2015)

PubMed=26055179; DOI=10.1016/j.tranon.2015.04.002
Vallo S., Michaelis M., Rothweiler F., Bartsch G., Gust K.M., Limbart D.M., Rodel F., Wezel F., Haferkamp A., Cinatl J. Jr.
Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics.
Transl. Oncol. 8:210-216(2015)

PubMed=26972028; DOI=10.1016/j.jprot.2016.03.008
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
Identification of glycosylphosphatidylinositol-anchored proteins and omega-sites using TiO2-based affinity purification followed by hydrogen fluoride treatment.
J. Proteomics 139:77-83(2016)

PubMed=27141528; DOI=10.1016/j.dib.2016.04.001
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
Data for identification of GPI-anchored peptides and omega-sites in cancer cell lines.
Data Brief 7:1302-1305(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

Cross-references
Cell line collections AddexBio; C0002001/8
ATCC; HTB-9
BCRC; 60061
BCRJ; 0026
CLS; 300105/p667_5637
DSMZ; ACC-35
ICLC; HTL01017
KCLB; 30009
NCBI_Iran; C450
RCB; RCB1191
RCB; RCB3676
TKG; TKG 0605
Cell line databases/resources CLDB; cl1
CLDB; cl105
CLDB; cl7118
CCLE; 5637_URINARY_TRACT
CCRID; 3131C0001000700001
Cosmic-CLP; 687452
GDSC; 687452
IGRhCellID; 5637
LINCS_HMS; 50001
LINCS_LDP; LCL-1702
SKY/M-FISH/CGH; 17
Ontologies BTO; BTO:0003137
CLO; CLO_0001421
CLO; CLO_0050845
EFO; EFO_0002096
MCCL; MCC:0000018
Biological sample resources BioSample; SAMN01821610
BioSample; SAMN03472760
BioSample; SAMN03473359
Chemistry resources ChEMBL-Cells; CHEMBL3308352
ChEMBL-Targets; CHEMBL612565
Gene expression databases GEO; GSM142303
GEO; GSM142309
GEO; GSM886840
GEO; GSM887903
GEO; GSM1374370
GEO; GSM1574578
GEO; GSM1669563
Polymorphism and mutation databases Cosmic; 687452
Cosmic; 715695
Cosmic; 760484
Cosmic; 845565
Cosmic; 846281
Cosmic; 928819
Cosmic; 943732
Cosmic; 1016892
Cosmic; 1046675
Cosmic; 1093983
Cosmic; 1285103
Cosmic; 1285998
Cosmic; 1927307
Cosmic; 2050427
Cosmic; 2057434
Cosmic; 2301520
Cosmic; 2444227
Proteomic databases PRIDE; PXD003105